We use cookies to improve the function of this site and enhance the user experience.
Learn more
about our cookie policy and how to modify your cookie settings.
UK/CORP/15-0012l. Date of preparation: July 2015
United Kingdom
Global Home
|
Contact Us
|
Site Map
|
Payments & Disclosures
|
Clinical Trials
Search
Include All CSL Behring Country Sites
About CSL Behring
Quality & Safety
CSL Research & Development
Healthcare Professionals
Patient Information
Customer Service
News
Useful Links
Home
> CSL Behring - UK Homepage
For Healthcare Professionals
CSL Behring is committed to improving the quality of life for patients with rare and serious diseases. The company develops, manufactures and markets a range of products including:
Coagulation therapies
For rapid warfarin reversal, von Willebrand disease, haemophilia and congenital fibrinogen deficiency
Immunology therapies
For hereditary angioedema, immune deficiency disorders, neurological disorders and haemolytic disease of the newborn
Healthcare professionals can access product SPCs via the links above
For Patients
Rapid warfarin reversal
Von Willebrand Disease
Haemophilia
Congenital Fibrinogen Deficiency
Immune Deficiency Disorders
Hereditary Angioedema
Haemolytic Disease of the Newborn
Neurological disorders
Customer Services
Further information on our products and how to order them.
Adverse events should be reported.
Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard
Adverse events should be reported to CSL Behring UK Ltd on 01444 447405